The multidisciplinary management of locally advanced rectal cancer
Expert Rev Anticancer Ther. 2024 Apr 26. doi: 10.1080/14737140.2024.2349137. Online ahead of print.ABSTRACTINTRODUCTION: . The classic paradigm for the management of locally advanced rectal cancer (LARC) consists of (chemo)radiotherapy (C)RT), total mesorectal excision and adjuvant chemotherapy (CHT). At present, due to the high rate of distant metastasis (up to 30%), the total neoadjuvant therapy (TNT) with the administration of systemic CHT in the neoadjuvant setting has gained acceptance as standard of care.Our aim is to critically review current literature on LARC management and summarize the different approaches recen...
Source: Expert Review of Anticancer Therapy - April 27, 2024 Category: Cancer & Oncology Authors: Francesca De Felice Michelangelo Miccini Andrea Botticelli Michela Roberto Niccol ò Petrucciani Source Type: research
A New Approach to Melanoma Treatment: microRNAs
Curr Top Med Chem. 2024 Apr 25. doi: 10.2174/0115680266291290240417081544. Online ahead of print.ABSTRACTAlthough immunotherapy and targeted therapy have radically changed melanoma treatment, the development of resistance and reduction of patient responses are still significant problems. Small molecule inhibitors are needed to overcome this situation, and biomarkers that can estimate whether patients will reply to existing treatments need to be developed. miRNAs are involved in diverse processes such as tumor development, tumor progression, metastasis, and invasion. While some miRNAs act as tumor suppressors, others may be...
Source: Current Topics in Medicinal Chemistry - April 27, 2024 Category: Chemistry Authors: Suleyman Ilhan Ferdi Oguz Harika Atmaca Source Type: research
Emerging immunotherapies in the Hodgkin Lymphoma Armamentarium
Expert Opin Emerg Drugs. 2024 Apr 27. doi: 10.1080/14728214.2024.2349083. Online ahead of print.ABSTRACTINTRODUCTION: Brentuximab vedotin and the PD-1 inhibitors have improved outcomes for classic Hodgkin lymphoma (cHL), but better therapies are needed for patients who relapse after these agents. Based on improved understanding of cHL biology, there is a robust pipeline of novel therapies in development. In this review, we highlight emerging immunotherapeutic agents and combinations for cHL.AREAS COVERED: We review clinical trials of novel PD-1/PD-L1 inhibitors beyond FDA-approved agents, checkpoint inhibitors targeting CT...
Source: Expert Opinion on Emerging Drugs - April 27, 2024 Category: Drugs & Pharmacology Authors: Michael A Spinner Ranjana H Advani Source Type: research
Corrigendum to "Small extracellular vesicles-mediated cellular interactions between tumor cells and tumor-associated macrophages: Implication for immunotherapy" [Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. Volume 1870(2) (2024), 166917 Article Number]
Biochim Biophys Acta Mol Basis Dis. 2024 Apr 26:167160. doi: 10.1016/j.bbadis.2024.167160. Online ahead of print.NO ABSTRACTPMID:38677963 | DOI:10.1016/j.bbadis.2024.167160 (Source: Biochimica et Biophysica Acta)
Source: Biochimica et Biophysica Acta - April 27, 2024 Category: Biochemistry Authors: Liaoran Niu Qi Wang Fan Feng Wanli Yang Zhenyu Xie Gaozan Zheng Wei Zhou Lili Duan Kunli Du Yiding Li Ye Tian Junfeng Chen Qibin Xie Aqiang Fan Hanjun Dan Jinqiang Liu Daiming Fan Liu Hong Jian Zhang Jianyong Zheng Source Type: research
Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance
Comb Chem High Throughput Screen. 2024 Apr 25. doi: 10.2174/0113862073296206240416060154. Online ahead of print.ABSTRACTChemotherapy resistance is a common cause of tumor treatment failure. Various molecular responses, such as increased expression of efflux transporter proteins, including Pglycoprotein (P-gp), changes in the tumor microenvironment (TME), the role of platelets, and the effects of cancer stem cells (CSCs), can lead to drug resistance. Through extensive research on the mechanisms of drug resistance, more effective anti-resistance drugs and therapeutic approaches are being developed. This review explores drug ...
Source: Combinatorial Chemistry and High Throughput Screening - April 27, 2024 Category: Chemistry Authors: Yun Liu Xinyu Sun Chen Wei Shoudong Guo Chunxiao Song Jiangyu Zhang Jingkun Bai Source Type: research
